TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03546283
Drug: Cattle Encephalon Glycoside and Ignotin
Normalized name: anthraquinone glycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients with hypertensive intracerebral hemorrhage will be randomized into giving CEGI, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
Study: NCT01786603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (looks like study drug but has no active ingredients) once a day for 12 months.
Study: NCT04251910
Drug: Sublingual Placebo Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual placebo film that matches BXCL501
Study: NCT01610245
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01610245
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04577846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo capsule filled with inert material for the duration of the drains which usually is about 14 days.
Study: NCT00532467
Drug: SRX251
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01003054
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg in 500 ml of normal saline over 4 hours on each of 2 consecutive days (day -3, -2)
Study: NCT01024010
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04649723
Drug: SHR1459
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose, 200 mg, fasted.
Study: NCT03340675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral placebo
Study: NCT03455491
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily during 3 days.
Study: NCT01427985
Drug: Atropine, Fentanyl, Mivacurium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Atropin 10µg/kg~2. Mivacurium 200µg/kg immediately followed by~3. Fentanyl 2µg/kg
Study: NCT01427985
Drug: Atropine, Fentanyl, Mivacurium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Atropin 10µg/kg~2. Fentanyl 2µg/kg, repeat max. two times~3. Mivacurium 200µg/kg
Study: NCT00435838
Drug: No Intervention -- Observational study
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01750346
Drug: Topical acetyl hexapeptide-8
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01750346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00487591
Drug: Omacor (omega-3-acid ethyl esters)plus simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omacor(omega-3-acid ethyl esters) - 4/g day (4 one gram capsules) simvastatin - 20 mg/day (1 tablet/20 mg)
Study: NCT00487591
Drug: simvastatin plus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 20mg/day (1 tablet 20 mg)plus 4 capsules matching placebo
Study: NCT00473343
Drug: Metvix® cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01136655
Drug: 80/2.25 μg Symbicort pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation
Study: NCT01136655
Drug: 80/4.5 μg Symbicort pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation
Study: NCT01136655
Drug: Foradil Aerolizer 12 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation
Study: NCT01136655
Drug: placebo HFA pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation
Study: NCT00704353
Drug: Standard Medical Care (SMC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per product label
Study: NCT03195088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection
Study: NCT04499963
Drug: Theracurmin HP
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is based on the twice daily dosage of Theracurmin 90 mg capsules used in a trial of patients with mild cognitive impairment
Study: NCT03982004
Drug: Intra-lesional GM-CSF
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mcg every 2 weeks x 3 doses then every 3 weeks for 3 doses
Study: NCT03216096
Drug: Placebo ophthalmic solution and 3% DE-089 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ophthalmic solution; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 2-week run-in period 3% DE-089 ophthalmic solution; ; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 4-week treatment period
Study: NCT01774435
Drug: EN3342
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00263029
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg tablets and 150mg tablets. 750mg/m² bd given approximately 12 hours apart
Study: NCT01289236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet (placebo) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period.
Study: NCT01981655
Drug: Hartmann's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hartmann's solution of 3 ml per kg BW is administered in 15 minutes, No infusion thereafter i.e. in total 3 ml per kg over 24 hours
Study: NCT03034564
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01673711
Drug: deuterated phenanthrene tetraol
Normalized name: pentaerythrityl tetraoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01673711
Drug: pharmacological study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Correlative studies
Study: NCT03572777
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin ('Amoksicilin') 1 g bid 14 days.
Study: NCT03572777
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin ('Makcin') 500 mg bid for 14 days
Study: NCT03572777
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole ('Medazol') 500 mg bid for 14 days
Study: NCT03572777
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole ('Emanera') 40 mg bid for 14 days
Study: NCT03572777
Drug: Hybrid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin ('Amoksicilin') 1 g bid 14 days
Study: NCT02676089
Drug: CHF 1535 200/6 µg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03572777
Drug: Hybrid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole ('Emanera') 40 mg bid for 14 days
Study: NCT03572777
Drug: Hybrid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin ('Makcin') 500 mg bid for the last 7 days
Study: NCT03572777
Drug: Hybrid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole ('Medazol') 500 mg bid for the last 7 days
Study: NCT00940693
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one capsule of placebo taken one a day for 6 weeks
Study: NCT00610987
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly assigned to one of two groups. Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo.
Study: NCT00050609
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken by mouth once a day for 8 weeks
Study: NCT03116698
Drug: High dose DFD07 once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose DFD07 once daily
Study: NCT03116698
Drug: High dose DFD07 twice daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High dose DFD07 twice daily
Study: NCT03116698
Drug: Placebo twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily
Study: NCT03001089
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
Study: NCT01483781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form = capsules, route = oral use. One capsule once daily for up to approximately 85 days (approximately 12 weeks)
Study: NCT00432614
Drug: SR58611A
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT00432614
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT01155362
Drug: Vehice Control
Normalized name: SUSPENDING VEHICLE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003398
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04360551
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT02386436
Drug: GSK2330811
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.
Study: NCT02386436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as Normal Saline (0.9% weight by volume \[w/v\] Sodium Chloride) administered as single dose s.c.
Study: NCT00520884
Drug: Ghrelin Infusion - Healthy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
Study: NCT00982865
Drug: MSC1936369B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02998775
Drug: Plasma Sampling
Approvals — FDA: no, EMA: no, PMDA: no
Description: No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Study: NCT02152332
Drug: JNJ-54861911-Therapeutic Dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.
Study: NCT03151863
Drug: Opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The usual opioid treatment used for nursing care
Study: NCT02645409
Drug: OTL38
Normalized name: Fluorodeoxyglucose F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTL38 is a folate analog conjugated with a fluorescent dye that emits light in the near infrared spectrum. This longer wavelength allows for deeper penetration of the fluorescent light through tissues with the potential to better image tumors beneath adipose tissue or deeper into organ parenchyma.
Study: NCT01615198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule
Study: NCT01615198
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, 200 mg tablets
Study: NCT03852251
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
Study: NCT03426371
Drug: KL-140
Approvals — FDA: no, EMA: no, PMDA: no
Description: KL-140 will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to KL-140.~Drug: Oxaliplatin Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m\^2/day intravenously followed by 2400 mg/m\^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
Study: NCT03426371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity Drug: Oxaliplatin Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m\^2/day intravenously followed by 2400 mg/m\^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
Study: NCT02833974
Drug: Placebo Nasal Spray Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Spray Solution as for GSK2245035 without active ingredient.
Study: NCT01593293
Drug: PemCarbo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500mg/m2, Carboplatin AUC5 intravenously q 3 weeks for 4 cycles, followed by pemtrexed 500mg/m2 q 3 weeks for maintenance therapy
Study: NCT04290858
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted concentration will have a tidal oscillation between 100 and 300 ppm, in order to maintain an average inhaled concentration from 140 to 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or trough a non-rebreathing mask without positive end expiratory pressure, depending on the clinical needs of the patient.
Study: NCT03161054
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Phase: Cyclophosphamide 50 mg/day will be orally administered from day 1 to day 21 (after dinner).~Maintenance Phase: 50 mg/day will be orally administered from day 1 to day 14 (after dinner).
Study: NCT00585143
Drug: ABT-335
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg once daily for 10 consecutive days
Study: NCT00585143
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg once daily for 10 days
Study: NCT01579188
Drug: GV1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection 0.84 mg ± 0.084 mg 3 times in Week 1 (Monday, Wednesday, and Friday) and once (Mondays) in Weeks 2, 3, 4, 6, 8, and 10, followed by boost injections given on Weeks 14, 18, 22, 26, and thereafter at 12 week intervals up to Week 98
Study: NCT01579188
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: two injections of normal saline injected in the same manner as the experimental drug, GV1001
Study: NCT03902509
Drug: basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: glucocorticoid and expectant treatment etc.
Study: NCT00177775
Drug: MucoMilk product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03703882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00625833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet once a day dosing for 10 weeks.
Study: NCT00747643
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this group received a placebo and did not receive any active medication according to the schedule in the Arm Description.
Study: NCT03632798
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent ovarian cancer.~Chemotherapy list:~* Liposomal Doxorubicin;~* Docetaxel;~* Paclitaxel;~* Carboplatin;~* Cisplatin;~* Gemcitabine;~* Topotecan;~* Carboplatin, Gemcitabine;~* Cisplatin, Gemcitabine;~* Carboplatin, Liposomal Doxorubicin;~* Carboplatin, Paclitaxel;~* Carboplatin, Docetaxel.
Study: NCT02956954
Drug: Enzyme replacement therapy (Agalsidase alpha (Replagal®))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient treated with Enzyme replacement therapy as usual (Agalsidase alpha (Replagal®)). The treatment is prescribed in routine and not specially for the protocol
Study: NCT01086462
Drug: GSK2239633
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ug GSK2239633 containing approximately 10kBq \[14C\]-GSK2239633
Study: NCT00907348
Drug: LR-CHOP21
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIRST DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 5 mg/day D1-D14~SECOND DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1;Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 10 mg/day D1-D14~THIRD DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 15 mg/day D1-D14~FOURTH DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 20 mg/day D1-D14 Repeated every 21 days
Study: NCT03321136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing mannitol looking identical to the other drugs.
Study: NCT02955940
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at the same dose provided in the parent study at the time of the rollover.
Study: NCT03171220
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide(CTX) 300mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
Study: NCT01517711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
Study: NCT01120002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two Tamibarotene 2 mg or placebo tablet per day, once daily.
Study: NCT03236311
Drug: SAR407899
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study: NCT03236311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study: NCT03236311
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study: NCT01035385
Drug: FOFLOX4
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4:Oxaliplatin 85mg/m2 ivgtt d1 2hr calcium leucovorin:200mg/m2 ivgtt d1 d2 2hr fluorouracil:400mg/m2 iv d1 d2 fluorouracil:600mg/m2 civ d1 d2 22hr 2 weeks repeated one cycles
Study: NCT02900443
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03575234
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04012931
Drug: ARV Background Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigator-selected ARVs, including but not limited to N(t)RTIs (example, azidothymidine \[AZT\], abacavir \[ABC\], tenofovir alafenamide \[TAF\], or tenofovir disoproxil fumarate \[TDF\] in combination with emtricitabine \[FTC\] or lamivudine \[3TC\]), whichever are approved and marketed or considered local standard of care for children aged between 2 and \< 12 years in a particular country are to be administered. Integrase inhibitors (for example, dolutegravir \[DTG\] or raltegravir) can also be administered in combination with RPV, as appropriate.
Study: NCT01517854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identical to Revatio (sildenafil citrate) three times a day
Study: NCT03427944
Drug: Calcium Dobesilate group
Normalized name: calcium dobesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate was used to treat patients with chronic renal failure on the basis of conventional treatment.
Study: NCT03427944
Drug: Conventional Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment were used to treat patients with chronic renal failure.
Study: NCT00431912
Drug: APO866
Approvals — FDA: no, EMA: no, PMDA: no
Description: APO866 is administered as 0.126 mg/m²/hr for 4 consecutive days (96 hours), every 3 weeks for a total of 3 cycles
Study: NCT03851250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomised to receive placebo will take it in addition to their regular asthma medication.
Study: NCT04388878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo
Study: NCT01206062
Drug: Standard control of SBP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the Standard BP arm have a goal of SBP \<140 mm Hg. The same medications used in the Intensive BP arm will be used for the Standard BP arm.
Study: NCT02244216
Drug: Berotec® N 100 µg Metered-dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no